NCT06975332View on ClinicalTrials.gov

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

NARecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
GlioblastomaHigh-Grade GliomasGrade III AstrocytomaGrade III Glioma
Interventions
RADIATION

Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.

Trial Locations (2)

02-097

RECRUITING

Department of Neurosurgery, Medical University of Warsaw, Banacha 1a, Warsaw

02-781

RECRUITING

Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5, Warsaw

All Listed Sponsors
lead

Medical University of Warsaw

OTHER